Coronary Stenosis

Categories: Cardiovascular diseases

Aliases & Classifications for Coronary Stenosis

MalaCards integrated aliases for Coronary Stenosis:

Name: Coronary Stenosis 12 54 43 15 17 71
Coronary Artery Stenosis 12 15


External Ids:

Disease Ontology 12 DOID:4248
MeSH 43 D023921
NCIt 49 C80427
SNOMED-CT 67 233970002
UMLS 71 C0242231

Summaries for Coronary Stenosis

MalaCards based summary : Coronary Stenosis, also known as coronary artery stenosis, is related to coronary artery vasospasm and inferior myocardial infarction, and has symptoms including angina pectoris An important gene associated with Coronary Stenosis is APOA1 (Apolipoprotein A1), and among its related pathways/superpathways are Lipoprotein metabolism and Metabolism of fat-soluble vitamins. The drugs Isosorbide Dinitrate and Nitric Oxide have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and endothelial, and related phenotypes are Decreased free cholesterol and Decreased LDL uptake

Related Diseases for Coronary Stenosis

Diseases related to Coronary Stenosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 565)
# Related Disease Score Top Affiliating Genes
1 coronary artery vasospasm 31.1 TNNI3 CRP ACE
2 inferior myocardial infarction 31.0 TNNI3 PIK3C2A NPPB
3 kawasaki disease 31.0 NPPB IL6 CRP ALB
4 angina pectoris 30.9 TNNI3 PIK3C2A NPPB IL6 CRP APOA1
5 intracranial embolism 30.9 CRP ALB ACE
6 infective endocarditis 30.8 TNNI3 SERPINE1 IL6 CRP
7 chlamydia 30.8 TLR4 IL6 CRP
8 right bundle branch block 30.8 TNNI3 NPPB ACE
9 ischemia 30.8 PON1 PIK3C2A NPPB ICAM1 CXCL12 ACE
10 anterolateral myocardial infarction 30.7 NPPB ACE
11 coronary aneurysm 30.7 IL6 CRP ALB
12 syphilis 30.6 IL6 CRP ALB ACE
13 atrioventricular block 30.6 TNNI3 PIK3C2A NPPB ACE
14 subendocardial myocardial infarction 30.6 SERPINE1 PIK3C2A
15 carotid stenosis 30.6 ICAM1 CRP APOE ACE
16 ischemic colitis 30.6 SERPINE1 CRP ACE
17 vasculitis 30.6 VWF IL6 ICAM1 CRP
18 coronary thrombosis 30.6 VWF SERPINE1 CRP ACE
19 aortic aneurysm 30.6 IL6 CRP APOE ACE
20 rheumatic heart disease 30.6 NPPB IL6 ACE
21 endocarditis 30.5 TNNI3 SERPINE1 PIK3C2A IL6 CRP ALB
22 chlamydia pneumonia 30.5 TLR4 IL6 CRP APOE
23 atrial heart septal defect 30.5 TNNI3 NPPB CRP ALB ACE
24 aortic disease 30.5 IL6 CRP APOE ACE
25 mitral valve disease 30.5 TNNI3 NPPB CRP ACE
26 hyperlipoproteinemia, type iii 30.5 LPL CETP APOE APOB APOA1
27 takayasu arteritis 30.4 VWF IL6 ICAM1 CRP
28 aortic aneurysm, familial abdominal, 1 30.4 IL6 CRP CETP APOE ACE
29 thrombocytosis 30.4 VWF IL6 CRP ALB
30 cardiogenic shock 30.4 PIK3C2A NPPB CRP
31 essential thrombocythemia 30.4 VWF SERPINE1 IL6 CRP
32 periodontitis 30.4 TLR4 IL6 ICAM1 CRP
33 cardiac arrest 30.3 PIK3C2A NPPB ICAM1 APOE ALB ACE
34 acute myocarditis 30.3 TNNI3 NPPB CRP ACE
35 left bundle branch hemiblock 30.3 TNNI3 PIK3C2A NPPB CRP ACE
36 migraine with or without aura 1 30.3 IL6 CRP APOE ALB ACE
37 plague 30.3 TLR4 IL6 ALB
38 proteasome-associated autoinflammatory syndrome 1 30.2 TLR4 IL6 ICAM1 CRP
39 anxiety 30.1 IL6 CRP APOE ACE
40 congestive heart failure 30.1 TNNI3 PIK3C2A NPPB IL6 CRP ALB
41 crohn's disease 30.1 TLR4 IL6 CRP ALB
42 end stage renal disease 30.1 PON1 IL6 CRP ALB ACE
43 neutropenia 30.1 TLR4 IL6 CRP ALB
44 deficiency anemia 30.1 PON1 IL6 CRP ALB ACE
45 homocysteinemia 30.1 VWF SERPINE1 PON1 CRP APOE ALB
46 ulcerative colitis 30.1 TLR4 IL6 ICAM1 CRP
47 mitral valve insufficiency 30.1 TNNI3 PIK3C2A NPPB CRP ALB ACE
48 antiphospholipid syndrome 30.0 VWF TLR4 SERPINE1 PON1 CRP
49 aortic valve insufficiency 29.9 VWF TNNI3 PON1 NPPB CRP ALB
50 pulmonary hypertension 29.9 VWF SERPINE1 NPPB IL6 CRP ALB

Graphical network of the top 20 diseases related to Coronary Stenosis:

Diseases related to Coronary Stenosis

Symptoms & Phenotypes for Coronary Stenosis

UMLS symptoms related to Coronary Stenosis:

angina pectoris

GenomeRNAi Phenotypes related to Coronary Stenosis according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 8.65 CXCL12
2 Decreased LDL uptake GR00340-A-1 8.32 LPL

MGI Mouse Phenotypes related to Coronary Stenosis:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.33 ACE ALB APOA1 APOB APOE CRP
2 homeostasis/metabolism MP:0005376 10.22 ACE ALB APOA1 APOB APOE CRP
3 cellular MP:0005384 10.15 ALB APOA1 APOB APOE CXCL12 ICAM1
4 immune system MP:0005387 10.07 ACE ALB APOB APOE CRP CXCL12
5 adipose tissue MP:0005375 9.98 ACE APOE IL6 LPL PIK3C2A SERPINE1
6 liver/biliary system MP:0005370 9.93 ACE ALB APOA1 APOB APOE CXCL12
7 mortality/aging MP:0010768 9.8 ACE ALB APOB APOE CXCL12 ICAM1
8 muscle MP:0005369 9.32 ALB APOB APOE CXCL12 ICAM1 IL6

Drugs & Therapeutics for Coronary Stenosis

Drugs for Coronary Stenosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 221)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
Nitric Oxide Approved Phase 4 10102-43-9 145068
AT-101 Approved, Investigational Phase 4 652-67-5, 90141-22-3 12597
Glucagon Approved Phase 4 16941-32-5
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
Liraglutide Approved Phase 4 204656-20-2 44147092
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
Iodine Approved, Investigational Phase 4 7553-56-2 807
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
Eplerenone Approved Phase 4 107724-20-9 150310 443872
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
12 Orange Approved Phase 4
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
Adenosine Approved, Investigational Phase 4 58-61-7 60961
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
Ticagrelor Approved Phase 4 274693-27-5 9871419
Edoxaban Approved Phase 4 480449-70-5
Fenofibrate Approved Phase 4 49562-28-9 3339
Atorvastatin Approved Phase 4 134523-00-5 60823
Cangrelor Approved Phase 4 163706-06-7 9854012
Nicorandil Approved, Investigational Phase 4 65141-46-0 47528
Adalimumab Approved Phase 4 331731-18-1 16219006
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
leucovorin Approved Phase 4 58-05-9 6006 143
Tofacitinib Approved, Investigational Phase 4 477600-75-2
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
Candesartan Experimental Phase 4 139481-59-7 2541
34 Tubulin Modulators Phase 4
35 Antimitotic Agents Phase 4
36 Trace Elements Phase 4
37 Nutrients Phase 4
38 Micronutrients Phase 4
39 Hormone Antagonists Phase 4
40 Incretins Phase 4
41 Hormones Phase 4
42 diuretics Phase 4
43 isosorbide-5-mononitrate Phase 4
44 Protective Agents Phase 4
45 Glucagon-Like Peptide 1 Phase 4
46 Vitamins Phase 4
47 Chlorhexidine gluconate Phase 4
48 cadexomer iodine Phase 4
49 Mineralocorticoids Phase 4
50 Mineralocorticoid Receptor Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 521)
# Name Status NCT ID Phase Drugs
1 Comparison of Fractional Flow Reserve and Minimal Luminal Area by Intravascular Ultrasound in Evaluating Intermediate Coronary Artery Stenosis in Each Coronary Artery Unknown status NCT01133015 Phase 4
2 Diagnostic Value of a Rapid Protocol Regadenoson Stress Cardiovascular Magnetic Resonance Scan for Detection of Coronary Artery Disease Unknown status NCT01446094 Phase 4 regadenoson
3 Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions Unknown status NCT00698607 Phase 4 6-month clopidogrel therapy;12-month clopidogrel therapy
4 Prospective Randomized Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions / BABILON Study (Paclitaxel-Coated Balloon in Bifurcated Lesions) Unknown status NCT01278186 Phase 4
5 A Developmental Clinical Study of Management Guided by Coronary Angiography Combined With Fractional Flow Reserve (FFR) Measurement Versus Management Guided by Coronary Angiography Alone(Standard Care) in Patients With Non-ST Elevation MI. Unknown status NCT01764334 Phase 4
6 A Phase IV Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Bio-Marker in Patients With Normal eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320 Completed NCT01137786 Phase 4 Non ionic contrast media comparator;Non ionic contrast media comparator
7 A Phase IV Pilot Study to Evaluate Kidney Damage Measured by Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Bio-Marker in Patients With Moderate Fall in eGFR Undergoing Percutaneous Coronary Intervention With IOPAMIDOL Injection 370 or IODIXANOL 320 Completed NCT01136876 Phase 4 Iopamidol;Iodixanol-320
8 Physiologic Evaluation of Anomalous Right Coronary Artery Stenosis Completed NCT01133054 Phase 4
9 A Randomized Double-blind Placebo-controlled Clinical Trials of the Blood-quickening Stasis-transforming Formula Quick-Acting Heart Reliever for Patients With Moderate Coronary Stenosis Completed NCT01513070 Phase 4 Quick-Acting Heart Reliever;Isosorbide Dinitrate;Placebo of Isosorbide Dinitrate;Aspirin Enteric-coated Tablets;Placebo of Quick-Acting Heart Reliever;Aspirin Enteric-coated Tablets
10 Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography (X-ACT Study) Completed NCT01255722 Phase 4 iobitridol;iopromide;iomeprol
11 EXecutive Randomized Controlled Trial (RCT): XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the Treatment of the Specific Setting of Patients With Multi-vessel Coronary Artery Disease. Completed NCT00531011 Phase 4
12 A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions Completed NCT01182428 Phase 4
13 A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions Completed NCT00496938 Phase 4
14 Effect of Rosuvastatin on Coronary Flow Reserve in Hypertensive Patients Completed NCT01490398 Phase 4 Rosuvastatin
15 Prospective Randomized Study of Unprotected Left Main Stenting Versus Bypass Surgery Completed NCT00375063 Phase 4
16 Comparison of Hyperemic Efficacy Between Central and Peripheral Adenosine Infusion for Fractional Flow Reserve (FFR) Measurement Completed NCT01070420 Phase 4
17 A Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients Completed NCT00755443 Phase 4
18 Effect of Glucagon-like Peptide-1 Stimulation on Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Obstructive Stenosis of Major Coronary Vessels Completed NCT02602600 Phase 4 Liraglutide
19 Excel Drug-Eluting Stent Pilot Clinical Registry Completed NCT00385905 Phase 4
20 Assessment of Coronary Flow Reserve and CT Angiography By Hybrid PET/CT: Relation to Clinically Indicated SPECT Studies Completed NCT00320931 Phase 4
21 Differential Effect of Ticagrelor vs Prasugrel or Clopidogrel Loading on Fractional Flow Reserve Completed NCT02108808 Phase 4 Ticagrelor;Prasugrel or Clopidogrel
22 SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions Completed NCT00402272 Phase 4
23 A Double-Blind, Multicenter, Placebo Controlled Study of Quinapril in Women With Chest Pain, Coronary Flow Reserve Limitations and Evidence of Myocardial Ischemia in the Absence of Significant Epicardial Coronary Artery Disease. Completed NCT00150826 Phase 4 Quinapril;Placebo
24 SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions Completed NCT01171820 Phase 4
25 Phase IV Study of Optimal Stenting Strategy For True Bifurcation Lesions Completed NCT00693251 Phase 4
26 (RTMPE for CAV) Real Time Myocardial Perfusion Echocardiography for Detection of Coronary Allograft Vasculopathy in Cardiac Transplant Patients Completed NCT02880137 Phase 4 Perflutren Lipid Microsphere
27 Model Project for the Reduction of Coronary Restenosis Completed NCT00627900 Phase 4
28 Vision II: Non Randomized French Evaluation of GALILEO Intravascular Radiotherapy System in Patients With de Novo Coronary Arteries Lesions by Restenosis on Angioplasty or Restenosis on Endoprosthesis Completed NCT00180583 Phase 4
29 A Double-Blind, Multicenter, Placebo Controlled Study of Aldosterone Blockade (Eplerenone) in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia in the Absence of Significant Epicardial Coronary Artery Disease Completed NCT00187889 Phase 4 Eplerenone;Placebo or sugar pill
30 Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson Completed NCT01779869 Phase 4 Regadenoson
31 Comparison of the Efficacy and Safety of Paclitaxel-Eluting CoroflexTM Please Stent Versus Paclitaxel-Eluting Stent in Patients With Coronary Artery Disease Completed NCT00995423 Phase 4
32 XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT) Completed NCT01178268 Phase 4
33 Diagnostic Value of Comprehensive Cardiothoracic Dual Source CT for the Early Triage of Patients With Undifferentiated Acute Chest Pain Completed NCT01067456 Phase 4
34 Sympathetic Heart Innervation in Patients With Previous Experience of Transient Stress-induced Cardiomyopathy (Tako-Tsubo): Effects of α-lipoic Acid and L-acetyl Carnitine Therapies. Completed NCT01524861 Phase 4 Placebo;alpha-lipoic acid;L-acetyl carnitine
35 Contrast Enhancement on Coronary Computed Tomographic Angiography : Effects on Intra-Coronary Attenuation Using Low Iodine Concentrations While Maintaining Identical IDR (EICAR-Trial) Completed NCT02462044 Phase 4 240 mg Iodine;300 mg Iodine;370 mg Iodine
36 DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity (DUTCH PEERS): Randomized Multicenter Trial in All Comers Population Treated Within Eastern NeThErlands-2 (TWENTE-2) Completed NCT01331707 Phase 4
37 Randomized Comparison of Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent Implantation for De Novo Coronary Artery DisEase in Patients With DIABETES Mellitus Completed NCT01186107 Phase 4
38 Randomized Comparison of Everolimus- Eluting Stent Versus Sirolimus-Eluting Stent Implantation for De Novo Coronary Artery DisEase in Patients With DIABETES Mellitus Completed NCT00997763 Phase 4
39 A Randomised, Open-label, Parallel Group, Multi-center Study Using OCT to Comparing the Efficacy and Safety of Ticagrelor With Clopidogrel in the Prevention of Subclinical Thrombus in Patients After Drug-eluting Stent Implantation Completed NCT02140801 Phase 4 Ticagrelor;Clopidogrel
40 Evaluation of Endothelial Progenitor Cell (EPC) Capturing (GENOUS) Stent After Coronary Stenting Utilizing Optical Coherence Tomography (OCT): the EGO Study Completed NCT01272895 Phase 4
41 The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting SteNt Study: Head-to-head Comparison of Clinical Outcome After Implantation of Second Generation Drug-eluting Stents in a Real World Scenario Completed NCT01066650 Phase 4
42 Fractional Flow Reserve - Guided Elective Coronary Angioplasty Using Paclitaxel - Eluting Balloons With Provisional Stent Implantation: A Phase 4 Feasibility Study With 6-Month Follow-up by Optical Coherence Tomography Completed NCT02120859 Phase 4
43 Phase 4 Study of Pioglitazone on Neointima Volume and Inflammatory Markers in Diabetic Patients Completed NCT00494559 Phase 4 Pioglitazone;Placebo
44 XIENCE V® Everolimus Eluting Coronary Stent System USA Post- Approval Study (XIENCE V® USA DAPT Cohort) (XVU-AV DAPT) Completed NCT01106534 Phase 4 placebo + aspirin;clopidogrel + aspirin OR prasugrel + aspirin
45 Endothelial Stent Coverage and Neointimal Proliferation at 6 Months After Implantation of a Coronary Everolimus-Eluting Stent Compared With a Bare Metal Stent Postdilated With a Paclitaxel-Eluting Balloon: A Randomised Study Using Optical Coherence Tomography Completed NCT01056744 Phase 4
46 Effects of Candesartan Cilexetil on Cardiovascular Events in Japanese Patients With Hypertension After Sirolimus- or Paclitaxel-Eluting Stents Implantation Completed NCT00139386 Phase 4 Candesartan
47 Comparison of the Efficacy and the Safety of Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent and PacliTaxel-Eluting Stent for Coronary Lesions Completed NCT00418067 Phase 4
48 Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth. A Clinical, Multi-center, Prospective, Non-Randomized Study Completed NCT00349895 Phase 4
49 Z-SEA-SIDE: Sirolimus Versus Everolimus Versus Zotarolimus-eluting Stent Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis Completed NCT01200693 Phase 4
50 SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis Completed NCT00697372 Phase 4

Search NIH Clinical Center for Coronary Stenosis

Cochrane evidence based reviews: coronary stenosis

Genetic Tests for Coronary Stenosis

Anatomical Context for Coronary Stenosis

MalaCards organs/tissues related to Coronary Stenosis:

Heart, Testes, Endothelial, Kidney, Liver, Neutrophil, Lung

Publications for Coronary Stenosis

Articles related to Coronary Stenosis:

(show top 50) (show all 8483)
# Title Authors PMID Year
The association between serum apolipoprotein A-I and apolipoprotein B and the severity of angiographical coronary artery disease. 61 54
19551315 2009
[Lipoprotein (a), D-Dimer and apolipoprotein A1 as markers of presence and severity of coronary disease]. 54 61
19386322 2009
Effect of statins on serum apolipoprotein j and paraoxonase-1 levels in patients with ischemic heart disease undergoing coronary angiography. 61 54
18403458 2008
[Level of alpha-granule membrane protein (CD62P) in coronary heart disease]. 61 54
18353216 2008
[Association between plasma adiponectin levels and coronary lesion complexity]. 54 61
18087549 2007
[Predictive value of lipoprotein (a) and apolipoprotein A1 in patients with angiographycally evaluated coronary stenosis]. 54 61
17524316 2007
The 3'-UTR C>T polymorphism of the oxidized LDL-receptor 1 (OLR1) gene does not associate with coronary artery disease in Italian CAD patients or with the severity of coronary disease. 61 54
16829343 2006
Association of plasma eotaxin levels with the presence and extent of angiographic coronary artery disease. 54 61
16084515 2006
Cholesteryl ester transfer protein gene polymorphisms and severity of coronary stenosis. 61 54
16553359 2006
Association of Leu125Val polymorphism of platelet endothelial cell adhesion molecule-1 (PECAM-1) gene & soluble level of PECAM-1 with coronary artery disease in Asian Indians. 61 54
15756041 2005
R643G polymorphism in PECAM-1 influences transendothelial migration of monocytes and is associated with progression of CHD and CHD events. 61 54
15488875 2004
Circulating ICAM-1, VCAM-1, E-selectin, P-selectin, and TNFRII in patients with coronary artery disease. 54 61
15495786 2004
Circulating ICAM-1, VCAM-1, E-selectin, P-selectin, and TNFalphaRII in patients with coronary artery disease. 54 61
14603993 2003
[Lipoprotein (a)--a mysterious factor in atherogenesis]. 61 54
12679978 2002
Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. 61 54
11171785 2001
Relationship between total plasma homocysteine, polymorphisms of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-based population. 61 54
10487496 1999
Plasma lipids, lipoproteins and apolipoproteins and sudden cardiac death. 61 54
10335875 1999
Clinical characteristics of double heterozygotes with familial hypercholesterolemia and cholesteryl ester transfer protein deficiency. 61 54
9242969 1997
Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. 54 61
8960946 1996
Characteristics of vasospastic angina with exercised-induced ischemia--analysis of parameters of hemostasis and fibrinolysis. 54 61
8803721 1996
Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. 54 61
7686453 1993
Evaluation of intracranial and extracranial atherosclerotic lesions in patients with symptomatic coronary artery disease. 61
32284016 2020
Outcomes of Patients With Coronary Arterial Bifurcation Narrowings Undergoing Provisional 1-Stent Treatment (from the BIONICS Trial). 61
32317100 2020
Percutaneous coronary intervention for left main coronary artery stenosis in a patient with dextrocardia. 61
31087254 2020
Surgical treatment of symptomatic left anterior descending myocardial bridges: myotomy vs. bypass surgery. 61
31893309 2020
Wellens' syndrome: a rare presentation after an endoscopic retrograde cholangiopancreatography. 61
32508130 2020
A direct comparison of 3 T contrast-enhanced whole-heart coronary cardiovascular magnetic resonance angiography to dual-source computed tomography angiography for detection of coronary artery stenosis: a single-center experience. 61
32475355 2020
Coronary 18F-Sodium Fluoride Uptake Predicts Outcomes in Patients With Coronary Artery Disease. 61
32553260 2020
Management and 5-year outcome of patients with coronary artery disease in different periods of stent technology. 61
32332377 2020
Prospective cardiovascular magnetic resonance imaging in adults with Alström syndrome: silent progression of diffuse interstitial fibrosis. 61
32503575 2020
Anomalous aortic origin of coronary arteries: an alternative to the unroofing strategy. 61
32572445 2020
Primary repair of transposition of the great arteries with an interrupted aortic arch: a case report and literature review. 61
32527284 2020
A randomized trial comparing the acute coronary, systemic, and environmental effects of electronic vaping cigarettes versus heat-not-burn cigarettes in smokers of combustible cigarettes undergoing invasive coronary assessment: rationale and design of the SUR-VAPES 3 trial. 61
32492988 2020
[Is FFRCT a game changer in coronary CT angiography?] 61
32494946 2020
Pericardial fat volume and coronary atherosclerotic markers among body mass index groups. 61
32492245 2020
Myocardial infarction with non-obstructive coronary arteries: what is the prognosis? 61
32523437 2020
Comparison of compressed sensing and conventional coronary magnetic resonance angiography for detection of coronary artery stenosis. 61
32563962 2020
(Epicardial and microvascular) angina or atypical chest pain: differential diagnoses with cardiovascular magnetic resonance. 61
32523454 2020
Optical coherence tomography-verified longer balloon inflation time may provide better stent apposition and optimal index parameters. 61
30191264 2020
Accuracy of computational pressure-fluid dynamics applied to coronary angiography to derive fractional flow reserve: FLASH FFR. 61
31693092 2020
Methodologic considerations on four cardiovascular interventions trials with contradictory results. 61
32540434 2020
Critical Left Main Coronary Stenosis After Sutureless Aortic Valve Replacement. 61
32479420 2020
Coronary Computed Tomography (CT) Angiography Characteristics of High-Risk Plaque: Correlation with Stress Myocardial Perfusion Imaging in Patients with Moderate Coronary Stenosis. 61
32495750 2020
Correlation of machine learning computed tomography-based fractional flow reserve with instantaneous wave free ratio to detect hemodynamically significant coronary stenosis. 61
31664509 2020
Quantitative imaging of coronary flows using 3D ultrafast Doppler coronary angiography. 61
32340010 2020
Optimal Stenting Technique for Complex Coronary Lesions: Intracoronary Imaging-Guided Pre-Dilation, Stent Sizing, and Post-Dilation. 61
32473888 2020
The "criminal" artery of de Winter may be the left circumflex artery: A CARE-compliant case report. 61
32541489 2020
Long-term outcomes following percutaneous coronary intervention to an unprotected left main coronary artery in cardiogenic shock. 61
32192748 2020
Clinical comparison study between a newly developed optical-based fractional flow reserve device and the conventional fractional flow reserve device. 61
31913164 2020
Characteristics of the left ventricular three-dimensional maximum principal strain using cardiac computed tomography: reference values from subjects with normal cardiac function. 61
32556462 2020

Variations for Coronary Stenosis

Expression for Coronary Stenosis

Search GEO for disease gene expression data for Coronary Stenosis.

Pathways for Coronary Stenosis

Pathways related to Coronary Stenosis according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
6 11.59 TLR4 IL6 ICAM1 CXCL12
Show member pathways
8 11.39 TLR4 IL6 ICAM1
9 11.35 IL6 ICAM1 APOB
Show member pathways
11 11.2 IL6 ICAM1 APOA1
12 11.09 TLR4 APOE ACE
13 10.92 SCARB1 APOB APOA1

GO Terms for Coronary Stenosis

Cellular components related to Coronary Stenosis according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.07 VWF SERPINE1 SCARB1 PON1 PIK3C2A ICAM1
2 cell surface GO:0009986 10.02 TLR4 SCARB1 PCSK9 LPL ICAM1 APOA1
3 collagen-containing extracellular matrix GO:0062023 9.97 VWF SERPINE1 ICAM1 CXCL12 APOE APOA1
4 early endosome GO:0005769 9.91 TLR4 PCSK9 APOE APOB APOA1
5 endoplasmic reticulum lumen GO:0005788 9.91 PCSK9 IL6 APOE APOB APOA1 ALB
6 blood microparticle GO:0072562 9.84 PON1 APOE APOA1 ALB
7 extracellular region GO:0005576 9.83 VWF SERPINE1 PON1 PCSK9 NPPB LPL
8 platelet alpha granule lumen GO:0031093 9.73 VWF SERPINE1 ALB
9 very-low-density lipoprotein particle GO:0034361 9.67 LPL APOE APOB APOA1
10 endocytic vesicle lumen GO:0071682 9.65 APOE APOB APOA1
11 low-density lipoprotein particle GO:0034362 9.63 APOE APOB APOA1
12 chylomicron GO:0042627 9.62 LPL APOE APOB APOA1
13 intermediate-density lipoprotein particle GO:0034363 9.58 APOE APOB APOA1
14 spherical high-density lipoprotein particle GO:0034366 9.57 PON1 APOA1
15 high-density lipoprotein particle GO:0034364 9.55 PON1 CETP APOE APOB APOA1
16 discoidal high-density lipoprotein particle GO:0034365 9.52 APOE APOA1
17 extracellular space GO:0005615 9.5 SERPINE1 PON1 PCSK9 NPPB LPL IL6

Biological processes related to Coronary Stenosis according to GeneCards Suite gene sharing:

(show all 49)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 10.15 PON1 PCSK9 LPL CETP APOE APOB
2 post-translational protein modification GO:0043687 10.09 PCSK9 IL6 APOE APOB APOA1 ALB
3 receptor-mediated endocytosis GO:0006898 10 SCARB1 APOE APOB APOA1 ALB
4 cellular protein metabolic process GO:0044267 9.99 PCSK9 IL6 APOE APOB APOA1 ALB
5 cellular response to lipopolysaccharide GO:0071222 9.98 TLR4 SERPINE1 IL6 ICAM1
6 lipid transport GO:0006869 9.97 SCARB1 CETP APOE APOB APOA1
7 steroid metabolic process GO:0008202 9.95 PCSK9 CETP APOE APOB APOA1
8 platelet degranulation GO:0002576 9.94 VWF SERPINE1 APOA1 ALB
9 retinoid metabolic process GO:0001523 9.89 LPL APOE APOB APOA1
10 phospholipid metabolic process GO:0006644 9.87 PCSK9 LPL APOA1
11 intermembrane lipid transfer GO:0120009 9.86 CETP APOE APOB APOA1
12 cholesterol metabolic process GO:0008203 9.85 PON1 PCSK9 CETP APOE APOB APOA1
13 phospholipid transport GO:0015914 9.83 SCARB1 CETP APOA1
14 triglyceride metabolic process GO:0006641 9.83 PCSK9 LPL CETP APOE
15 low-density lipoprotein particle clearance GO:0034383 9.81 SCARB1 PCSK9 APOB
16 positive regulation of cholesterol efflux GO:0010875 9.8 PON1 APOE APOA1
17 phosphatidylcholine metabolic process GO:0046470 9.8 PON1 CETP APOA1
18 low-density lipoprotein particle remodeling GO:0034374 9.79 CETP APOE APOB
19 lipoprotein metabolic process GO:0042157 9.78 PCSK9 APOE APOB APOA1
20 high-density lipoprotein particle clearance GO:0034384 9.76 SCARB1 APOE APOA1
21 cholesterol transport GO:0030301 9.76 SCARB1 CETP APOB APOA1
22 chylomicron assembly GO:0034378 9.74 APOE APOB APOA1
23 cholesterol efflux GO:0033344 9.73 SCARB1 APOE APOB APOA1
24 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.71 TLR4 LPL
25 positive regulation of cholesterol storage GO:0010886 9.71 SCARB1 LPL APOB
26 reverse cholesterol transport GO:0043691 9.71 SCARB1 CETP APOE APOA1
27 phospholipid homeostasis GO:0055091 9.7 CETP APOA1
28 phospholipid efflux GO:0033700 9.7 APOE APOA1
29 cholesterol catabolic process GO:0006707 9.7 SCARB1 APOE
30 blood vessel endothelial cell migration GO:0043534 9.7 SCARB1 APOA1
31 negative regulation of lipid storage GO:0010888 9.69 IL6 CRP
32 chylomicron remnant clearance GO:0034382 9.69 APOE APOB
33 positive regulation of cholesterol esterification GO:0010873 9.68 APOE APOA1
34 neutrophil mediated immunity GO:0002446 9.68 IL6 ACE
35 regulation of Cdc42 protein signal transduction GO:0032489 9.68 APOE APOA1
36 cholesterol import GO:0070508 9.67 SCARB1 APOA1
37 very-low-density lipoprotein particle clearance GO:0034447 9.67 APOE APOB
38 positive regulation of chemokine (C-C motif) ligand 2 secretion GO:1904209 9.67 TLR4 LPL
39 lipoprotein biosynthetic process GO:0042158 9.67 APOE APOB APOA1
40 lipoprotein catabolic process GO:0042159 9.66 APOE APOB
41 adhesion of symbiont to host GO:0044406 9.65 SCARB1 ICAM1
42 detection of lipopolysaccharide GO:0032497 9.65 TLR4 SCARB1
43 positive regulation of phospholipid efflux GO:1902995 9.65 APOE APOA1
44 positive regulation of low-density lipoprotein particle receptor catabolic process GO:0032805 9.64 PCSK9 APOE
45 very-low-density lipoprotein particle remodeling GO:0034372 9.62 LPL CETP APOE APOA1
46 chylomicron remodeling GO:0034371 9.56 LPL APOE APOB APOA1
47 triglyceride homeostasis GO:0070328 9.55 SCARB1 LPL CETP APOE APOA1
48 high-density lipoprotein particle remodeling GO:0034375 9.35 SCARB1 CETP APOE APOA1 ALB
49 cholesterol homeostasis GO:0042632 9.17 SCARB1 PCSK9 LPL CETP APOE APOB

Molecular functions related to Coronary Stenosis according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 phospholipid binding GO:0005543 9.76 PON1 APOE APOB APOA1
2 amyloid-beta binding GO:0001540 9.71 TLR4 SCARB1 APOE APOA1
3 signaling receptor binding GO:0005102 9.7 TLR4 SERPINE1 NPPB LPL CXCL12 APOE
4 lipid transporter activity GO:0005319 9.65 APOE APOB APOA1
5 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.54 APOE APOA1
6 apolipoprotein binding GO:0034185 9.54 SCARB1 PCSK9 LPL
7 lipopolysaccharide receptor activity GO:0001875 9.52 TLR4 SCARB1
8 very-low-density lipoprotein particle receptor binding GO:0070326 9.51 PCSK9 APOE
9 low-density lipoprotein particle binding GO:0030169 9.5 SCARB1 PCSK9 CRP
10 apolipoprotein receptor binding GO:0034190 9.49 PCSK9 APOA1
11 triglyceride binding GO:0017129 9.43 LPL CETP
12 lipoprotein particle binding GO:0071813 9.43 LPL APOE APOA1
13 low-density lipoprotein particle receptor binding GO:0050750 9.26 PCSK9 CRP APOE APOB
14 intermembrane cholesterol transfer activity GO:0120020 8.92 CETP APOE APOB APOA1

Sources for Coronary Stenosis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....